regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-08 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AMPylation of the IbpA Fic domain of Rho family GTPases is responsible for its cytotoxicity. Both Fic domains have similar effects on host cells' cytoskeleton as VopS. The AMPylation on a tyrosine residue of the switch 1 region blocks the interaction of the GTPases with downstream substrates such as PAK. DrrA is the Dot/Icm type IV translocation system substrate DrrA from Legionella pneumophila. It is the effector secreted by L. pneumophila to modify GTPases of the host cells. This modification increases the survival of bacteria in host cells. DrrA is composed of Rab1b specific guanine nucleotide exchange factor (GEF) domain, a C-terminal lipid binding domain and an N-terminal domain with unclear cytotoxic properties. Research works show that N-terminal and full-length DrrA shows AMPylators activity toward host's Rab1b protein (Ras related protein), which is also the substrate of Rab1b GEF domain. Rab1b protein is the GTPase Rab to regulate vesicle transportation and membrane fusion. The adenylation by bacteria AMPylators prolong GTP-bound state of Rab1b. Thus, the role of effector DrrA is connected toward the benefits of bacteria's vacuoles for their replication during the infection.
While there are multiple proposed explanations for how SARS-CoV-2 was introduced into and evolved adaptations suited to human populations, there is significant evidence and agreement that the most likely original viral reservoir for SARS-CoV-2 is horseshoe bats. The closest known viral relatives of SARS-CoV-2 are BANAL-52 and RaTG13, sampled from horseshoe bat droppings in Feuang, Laos, and Yunnan province in China respectively. The evolutionary distance between SARS-CoV-2 and RaTG13 is estimated to be about 50 years (between 38 and 72 years). Bats are a significant reservoir species for a diverse range of coronaviruses, and humans have been found with antibodies for them suggesting that direct infection by bats is common. The zoonotic transmission of SARS-CoV-2 virus to humans took place in the context of exacerbating factors that could make such spillovers more likely. Human contact with bats has increased as human population centers encroach on bat habitats. Several social and environmental factors including climate change, natural ecosystem destruction and wildlife trade have also increased the likelihood for the emergences of zoonosis. One study made with the support of the European Union found climate change increased the likelihood of the pandemic by influencing distribution of bat species. The earliest human cases of SARS-CoV-2 were identified in Wuhan, but the index case remains unknown.
==== Salmonella and copper ==== The FDA released a video focusing on another major threat in commercial pet food: Salmonella bacterial contamination. They also cite other major toxins of concern. The video references the case of a specific commercial pet food plant that was also the subject of a March 2014 study published in the Journal of the American Veterinary Medical Association. It details how at least 53 known human illnesses were linked to commercial pet foods made at that plant in 2012. A class action lawsuit linked to this outbreak was settled in 2014. The video also cites the dangers of over supplementation of nutrients in pet food. A study published in the Journal of the American Veterinary Medical Association in February 2013 suggested a correlation between liver disease and the amount of copper supplementation in AAFCO diets.
== Composition == Diatomaceous earth consists of the fossilized remains of diatoms that accumulated over millions of years. It is usually composed of 80% to 90% silica, 2% to 4% alumina minerals, and 0.5% to 2% iron oxide, although the precise composition of every deposit is different. Deposits may contain different amounts of silica depending on the sedimentation conditions, the presence of other sediments (clay, sand, volcanic ashes), and the age of the deposit (diagenesis, silica (SiO2) dissolution/precipitation, diatoms tests ageing). The species of diatom may also differ among deposits. The species of diatom is dependent upon the age and paleoecology of the deposit. In turn, the shape of a diatom is determined by its species. Many deposits throughout British Columbia, such as Red Lake Earth, are from the Miocene epoch and contain a species of diatom known as Melosira granulata. These diatoms have a small globular shape. A deposit containing diatoms from this epoch can provide certain benefits over others. For example, diatoms from the Eocene epoch are not as effective in their ability to absorb fluids because as older diatoms recrystallize, their small pores become filled with silica.
Sources: en.wikipedia.org
Ammonium formate can be used as a mobile phase additive in high performance liquid chromatography (HPLC), and is suitable for use with liquid chromatography-mass spectrometry (LC/MS). The pKa values of formic acid and the ammonium ion are 3.8 and 9.2, respectively.
=== 1974 === 16 April: Thérèse Siegenthaler (21). A sociology student at Greenwich Community College, Siegenthaler was abducted by the Wests as she hitchhiked from South London to Holyhead. Fred mistook her Swiss accent for Dutch and always referred to her as either "the Dutch girl" or "Tulip". She was reported missing to Scotland Yard by her family in Switzerland when communication from their daughter abruptly ceased. Fred later further concealed Siegenthaler's remains by building a false chimney breast on her grave. 15 November: Shirley Hubbard (15). A foster child abducted from a Droitwich bus stop close to the River Severn as she travelled home from a date. Aged 15 when murdered, Hubbard had been attending work experience in Worcester and was last seen by her boyfriend, having promised to meet him the next day. Her dismembered remains were found in a section of the cellar known to the family as the "Marilyn Monroe area". Hubbard's head had been completely covered in tape, with a one-eighth-inch (3.2 mm) diameter rubber tube inserted three inches (7.6 cm) into her nasal cavity to enable her to breathe.
=== Regeneration === All cnidarians can regenerate, allowing them to recover from injury and to reproduce asexually. Medusae have limited ability to regenerate, but polyps can do so from small pieces or even collections of separated cells. This enables corals to recover even after apparently being destroyed by predators.
Sources: en.wikipedia.org
== Other uses == VIP style, or VIP Car, a car modification trend Plymouth VIP, a luxury version of the Plymouth Fury (1966-1969) Vacuum insulated panel, a form of thermal insulation consisting of a nearly gas-tight enclosure surrounding a rigid core, from which the air has been evacuated Variable Information Printing, a form of on-demand printing VimpelCom, a stock symbol VIP Ecuador, an Ecuadorian airline VIP Industries, a luggage manufacturer based in India VIP's (restaurant), an American restaurant chain Virgil Partch, a cartoonist who signed his work Vip Virgin Islands Party, a political party in the British Virgin Islands Virology Science and Technology Institute of the Philippines, also known as the Virology Institute of the Philippines (VIP) Vision Inspired by the People, a political party in Belize Visually impaired person, a person with a decreased ability to see
As radioactive iodine treatment results in the destruction of thyroid tissue, there is often a transient period of several days to weeks when the symptoms of hyperthyroidism may worsen following radioactive iodine therapy. In general, this happens as a result of thyroid hormones being released into the blood following the radioactive iodine-mediated destruction of thyroid cells that contain thyroid hormone. In some people, treatment with medications such as beta blockers (propranolol, atenolol, etc.) may be useful during this period. Most people do not experience any difficulty after the radioactive iodine treatment, usually given as a small pill. On occasion, neck tenderness or a sore throat may become apparent after a few days, if moderate inflammation in the thyroid develops and produces discomfort in the neck or throat area. This is usually transient, and not associated with a fever, etc. It is recommended that breastfeeding be stopped at least six weeks before radioactive iodine treatment and that it not be resumed, although it can be done in future pregnancies. It also shouldn't be done during pregnancy, and pregnancy should be put off until at least 6–12 months after treatment. A common outcome following radioiodine is a swing from hyperthyroidism to easily treatable hypothyroidism, which occurs in 78% of those treated for Graves' thyrotoxicosis and in 40% of those with toxic multinodular goiter or solitary toxic adenoma.
=== Relation to acupuncture === The debated distinction between dry needling and acupuncture has become a controversy because it relates to an issue of scope of practice of various professions. Acupuncturists claim that dry needling is a form of acupuncture that does not fall in the scope of physical therapists, chiropractors, or the majority of other healthcare professionals; whereas those healthcare professionals claim dry needling is not acupuncture, but rather a procedure that is rooted in biomedical modern sciences. Becoming a certified acupuncturist requires hundreds of hours spent in educational programs, national-level exams, and good professional standing. On the other hand, to be certified in dry needling requires continued education or a certification program that is not yet regulated with strict standards; in addition, there is a general lack of policymakers, evaluation systems, or healthcare standards governing the technique of dry needling. Many physical therapists and chiropractors have asserted that they are not practicing acupuncture when dry needling; however, much of dry needling research has been done concerning acupuncture. They assert that much of the basic physiological and biomechanical knowledge that dry needling utilizes is taught as part of their core physical therapy and chiropractic education and that the specific dry needling skills are supplemental to that knowledge and not exclusive to acupuncture.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.